BRCA2 and ovarian carcinoma: Besides the use of the MLPA, or other multiplex approaches, to test the effect of genetic variants predicted to affect splicing at the RNA level, it would be useful to test for BRCA1 and BRCA2 mutation negative patients with strong breast and/or ovarian cancer history.